AT&T Faces $4.5 Billion Cash Flow Hurdle as Stock Eyes Next Move
Revolution Medicines’ daraxonrasib doubled median survival to 13.2 months versus 6.7 for chemo in a 500-patient Phase 3 pancreatic cancer trial; risk of death cut by 60%. RVMD last quoted at $157.48 premarket, market cap $31.2B. FDA has allowed expanded access but drug remains unapproved. Company plans global regulatory filings; $1.9B cash at March 31 plus $2.1B from April financings. Q1 net loss widened to $453.8M.